AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Dupixent is generally dosed every two or four weeks for AD. At the American Academy of Dermatology (AAD) congress in San Diego, data from STEAM-AD showed that amlitelimab achieved sustained ...

THE TV – “Feel tired? Out of energy? Then you need Oxyoxt.” “I used to have broken bones, cancer of the thumbs and nightmares ...

The real shock was what didn’t appear on screen: a 30-second ad that plays before almost every film at AMC theaters. Since it first appeared four years ago, few things have divided moviegoers ...

Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.

(Reuters) - Regeneron (NASDAQ: REGN) Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing ...

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.